CGEM
CGEM clinical trials: Cullinan Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Cullinan Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 12
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
CGEM on the catalyst calendar · CGEM registry changes
- Primary completion Sep 30, 2027Sponsor estimatePhase 1NCT07722767A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML PatientsCullinan Therapeutics Inc. · AML (Acute Myeloid Leukemia)Not yet recruitingCGEMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2029Sponsor estimatePhase 1/Phase 2NCT05143996CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)Cullinan Therapeutics Inc. · Relapsed/Refractory Acute Myeloid Leukemia (AML)RecruitingCGEMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT06613360A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusCullinan Therapeutics Inc. · SLERecruitingCGEMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2027Sponsor estimatePhase 1NCT06994143A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid ArthritisCullinan Therapeutics Inc. · Rheumatoid Arthritis (RARecruitingCGEMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2024ActualPhase 1NCT05879744A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)Cullinan Therapeutics Inc. · NHLTerminatedCGEMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 15, 2028Sponsor estimatePhase 1NCT07041099A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's DiseaseCullinan Therapeutics Inc. · SjögrenRecruitingCGEMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2029Sponsor estimatePhase 1/Phase 2NCT07738822A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHACullinan Therapeutics Inc. · Immune Thrombocytopenia (ITP)Not yet recruitingCGEMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 16, 2026ActualPhase 1NCT06035744CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid TumorsCullinan Therapeutics Inc. · Advanced Solid TumorTerminatedCGEMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2025ActualPhase 1/Phase 2NCT04036682A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung CancerCullinan Therapeutics Inc. · Non Small Cell Lung CancerActive, not recruitingCGEMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2026Sponsor estimatePhase 1NCT05117476A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid TumorsCullinan Therapeutics Inc. · Advanced Solid TumorActive, not recruitingCGEMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2026Sponsor estimatePhase 1NCT06381141A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple MyelomaCullinan Therapeutics Inc. · Multiple MyelomaActive, not recruitingCGEMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 23, 2020ActualPhase 1/Phase 2NCT03682055Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)Cullinan Therapeutics Inc. · Nasopharyngeal CarcinomaTerminatedCGEMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner